Klaria Pharma Holding AB (publ)

Klaria Pharma Holding AB (publ) has a market capitalization of 3.92 billion SEK and a price-to-book ratio of 134.33, indicating a highly leveraged equity valuation relative to its book value. The company's liquidity position is weak, with a current ratio of 0.08 and no long-term debt, but only 919,000 SEK in cash and equivalents, which is insufficient to cover its operating cash outflows of 7.83 million SEK. The company's return on equity is -40.7%, and its return on assets is -17.31%, both significantly below industry norms for a biotechnology firm. The company's operating income is -7.58 million SEK, and its net income is -11.89 million SEK, reflecting a challenging profitability position. These figures are far below the median for its industry, which typically shows positive operating and net margins. The company's revenue of 123 million SEK is modest, and its operating cash flow is negative, indicating a reliance on external financing to sustain operations. Klaria's revenue is not segmented by geographic region or product line in the available data, but the company's total assets of 68.67 million SEK and total liabilities of 39.46 million SEK suggest a relatively small asset base. The absence of capital expenditures and the lack of long-term debt indicate a conservative capital structure, but also limited investment in growth. Looking ahead, the company's revenue outlook is uncertain, with no clear growth trajectory evident from the data. The absence of analyst price targets beyond 0.97 SEK suggests a lack of consensus on the company's future value. The company's risk assessment indicates low liquidity and dilution risk, but the absence of positive cash flows and the high price-to-book ratio suggest a speculative investment profile. Recent filings and transcripts do not provide additional insight into the company's strategic direction or operational performance. The company's financial position remains precarious, with no immediate signs of improvement in profitability or liquidity. The lack of analyst price targets and the absence of capital expenditures further underscore the company's limited growth prospects.